Steve Chaplin, Surya Rajeev and John Wilding December 9, 2015 26.11 5 June 2015
Empagliflozin (Jardiance) is the third SGLT2 inhibitor available for the treatment of type 2 diabetes. Here we present the clinical data relating to its efficacy and adverse events.
Jardiance the latest SGLT2 for the treatment of type 2 diabetes
PrescriberMailing list request
Registration is for health professionals only and gives free access to our content.
Your Name (required)
Your Email (required)
Job Title (required)
---CCGCommunity NurseCommunity PharmacistGPGP prescribing leadNon-medical PrescriberPractice NursePractice PharmacistOther (specify below)
Other Job Title
Would you also like to receive the print title?
Yes (please complete address details below)No
Address Line 1
Address Line 2
By submitting your email address you consent to receive occasional relevant email alerts from Prescriber. Your email will not be shared with any third party. Please note you can opt out by replying to any email with the words ‘unsubscribe’.